Phase II single-arm, multi-center trial of BGB-A317 patients with previously treated, PD-L1-positive, locally advanced or metastatic urothelial cancer (UC).

Trial Profile

Phase II single-arm, multi-center trial of BGB-A317 patients with previously treated, PD-L1-positive, locally advanced or metastatic urothelial cancer (UC).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs BGB A317 (Primary)
  • Indications Bladder cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors BeiGene
  • Most Recent Events

    • 07 Jul 2017 New trial record
    • 05 Jul 2017 According to a BeiGene media release, Professor Dingwei Ye of the Fudan University Shanghai Cancer Center is the lead principal investigator of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top